Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Oncogenesis|December 17, 2013
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2A A Arbini, F Guerra, M Greco, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient populationS P Kim, C P Gross, M C Smaldone, et al.
British Journal of Cancer|August 29, 2013
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladderE Xylinas, M Kent, L Kluth, et al.
Prostate Cancer and Prostatic Diseases|September 4, 2013
Impact of statin use on biochemical recurrence in patients treated with radical prostatectomyM Rieken, L A Kluth, E Xylinas, et al.
World Journal of Urology|October 13, 2016
Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tractG J Wirth, A Haitel, M Moschini, et al.
Oncogene|February 16, 2016
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapiesJ Zhou, J Luo, K Wu, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 12, 2013
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinomaM Rieken, E Xylinas, L Kluth, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 1, 2014
Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinomaM Rieken, T Schubert, E Xylinas, et al.
British Journal of Cancer|July 9, 2014
Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessmentL A Kluth, F Abdollah, E Xylinas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Pageof 4